STOCK TITAN
  1. Home
  2. News
  3. TEVA

Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.

Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:

  • Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
  • Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
  • Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.

In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.

Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.

Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.

News

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Rhea-AI Summary
Teva Pharmaceuticals Inc. (TEVA) receives approval for a generic version of Forteo® (teriparatide injection) to treat osteoporosis in the US, showcasing their strengths in complex generic formulations development and device engineering. The market availability of the product is expected in the coming weeks. The approval aims to enhance access to a critical treatment option for patients, aligning with Teva's strategic goal of sustaining a generic powerhouse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
News

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) collaborates with Royalty Pharma plc (Nasdaq: RPRX) to accelerate the clinical research program for olanzapine LAI (TEV-‘749) by receiving up to $125 million in funding. Olanzapine LAI is a long-acting subcutaneous injectable olanzapine for schizophrenia currently in Phase 3. The collaboration aims to support the development of this potential first long-acting olanzapine with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
News

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported Q3 2023 revenues of $3.9 billion, reflecting a 7% increase from Q3 2022, with a revised 2023 outlook of $15.1 - $15.5 billion. Strong performance of AUSTEDO®, AJOVY®, and the global generics business drove revenue growth. Non-GAAP diluted EPS was $0.60, with cash flow generated from operating activities of $5 million and free cash flow of $229 million. Exclusive collaboration with Sanofi on Anti TL1-A (TEV-‘574) and accelerated Phase 3 results for Olanzapine LAI (TEV-‘749) were highlighted. Teva api's new CEO and management team were announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
earnings
News

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) appoints Dr. R. Ananthanarayanan as CEO of Teva Active Pharmaceutical Ingredients business, signaling a pivotal time for the company's strategy and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
management
-
News

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting

Rhea-AI Summary
Teva Pharmaceuticals announced that 92% of patients with Huntington's disease achieved optimal dosing with AUSTEDO using a 4-week patient titration kit. Additional results showed the efficacy and tolerability of AUSTEDO. AUSTEDO remains the only VMAT2 inhibitor with 3-year data for Huntington's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
-
News

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

Rhea-AI Summary
Teva Pharmaceuticals announces efficacy and safety findings from the phase 3 RISE study, supporting the FDA approval of UZEDY as a long-acting injectable antipsychotic treatment for adults with schizophrenia. UZEDY significantly prolonged time to impending relapse by up to 5.0 times versus placebo, with once-monthly dosing showing an 80% decreased risk of relapse. The safety profile of UZEDY was consistent with other formulations of risperidone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
News

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Rhea-AI Summary
Data from the UNITE study presented at the World Congress of Neurology shows that AJOVY® (fremanezumab) reduces migraine attacks and depression symptoms in migraine patients with major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
clinical trial
-
News

Teva Leverages Market-leading Temperature & Theft Tracking from FourKites to Deliver Critical Medicines Around the World

Rhea-AI Summary
Teva achieves 0.005% incident rate with FourKites' global carrier visibility solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
News

Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023

Rhea-AI Summary
Teva Pharmaceutical Industries to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.37%
Tags
conferences earnings
News

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Rhea-AI Summary
Sanofi and Teva Pharmaceuticals announce a collaboration to co-develop and co-commercialize asset TEV '574, a therapy for ulcerative colitis and Crohn's disease. Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Initial program results expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none

FAQ

What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is $17.12 as of November 22, 2024.

What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is approximately 19.2B.

What does Teva Pharmaceutical Industries Limited specialize in?

Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.

Where is Teva headquartered?

Teva is headquartered in Tel Aviv, Israel.

What are some of Teva's key products?

Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.

In which regions does Teva operate?

Teva operates in North America, Europe, Japan, Russia, and Israel.

How much of Teva's sales come from North America?

Approximately 50% of Teva's sales come from North America.

What therapeutic areas does Teva focus on?

Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.

What is Anda?

Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.

Does Teva offer contract manufacturing services?

Yes, Teva offers contract manufacturing services.

What role does Teva play in the U.S. generic prescription market?

Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.

What recent advancements has Teva made?

Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.

Stock TEVA logo
Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

#576 Ranked by Market Cap
N/A Ranked by Dividends

TEVA Stock Data

19.22B
1.13B
0%
57.25%
1.6%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TEL AVIV